Search

Objective: To prospectively compare full dose gadopentetate dimeglumine (Gd-DTPA) with full dose gadobenate dimeglumine (Gd-BOPTA) in the detection of focal hepatic lesions in patients with chronic liver disease on MRI. Materials and Methods: Eight patients with hepatic cirrhosis and a strong suspicion for small hepatocellular carcinoma based on prior MRI underwent contrast-enhanced MR examinations, one with full dose Gd-DTPA and one with full dose Gd-BOPTA. The exams were performed from 72–108 hours apart. Two blinded and independent radiologists evaluated images for lesion number, characterization, enhancement, and subjective preference. Results: There was no statistically significant difference between the two studies for lesion detection or characterization. There was 18% increased lesion enhancement for Gd-BOPTA, compared to Gd-DTPA, of the dominant lesion. Both blinded readers subjectively preferred the images using Gd-BOPTA over Gd-DTPA in the majority of cases, based on greater lesion enhancement and better edge definition. Conclusion: At equivalent full doses, Gd-BOPTA compared similarly with Gd-DTPA in the detection and characterization of focal hepatic lesions in patients with chronic liver disease. However, Gd-BOPTA was superior for increased lesion enhancement and subjective preference of the reader. [ABSTRACT FROM AUTHOR]

Copyright of Radiologia Brasileira is the property of Radiologia Brasileira and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)